RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Mendus AB (publ) Stock

Mendus AB (publ) Market capitalization 2024

Mendus AB (publ) Market capitalization

189.85 M SEK

Ticker

IMMU.ST

ISIN

SE0005003654

WKN

A1W59F

In 2024, Mendus AB (publ)'s market cap stood at 189.85 M SEK, a 3.23% increase from the 183.91 M SEK market cap in the previous year.

The Mendus AB (publ) Market capitalization history

YEARMarket Capitalization (undefined SEK)
20230.46
20220.47
20210.94
202013.88
201912.46
20186.96
20178.24
201612.94
201510.6
20147.68
20136.91
2012-
2011-
2010-
2009-
2008-
2007-

Mendus AB (publ) Aktienanalyse

What does Mendus AB (publ) do?

Immunicum AB is a biopharmaceutical company based in Stockholm, Sweden. It was founded in 2002 and has been working on developing innovative cancer therapies. The company aims to fight cancer cells in the body by targeting the activation of the body's immune system. Immunicum's business model is based on developing therapies that utilize allogeneic cell therapy. This involves using cells from donors to support specific processes in the body. Immunicum focuses on using dendritic cells as a model to specifically activate the body's immune system and fight cancer cells. The company has various divisions involved in the value chain of cancer therapy. One important area is the research and development of immunotherapies based on allogeneic cell therapy. Dendritic cells in particular are studied and further developed to enhance their effectiveness in fighting cancer. Another important division of Immunicum is clinical development, which involves conducting clinical trials to test and demonstrate the efficacy of the developed therapies in controlled studies. The results can then be used to seek approval for the therapies from regulatory authorities. Commercial development is another crucial area for Immunicum, involving the marketing and sale of the developed therapies. The company works closely with partners in the pharmaceutical industry to distribute the therapies worldwide and make them accessible to patients. Currently, the key product of Immunicum is the medication ilixadencel, which is a therapy based on allogeneic cell therapy that activates dendritic cells. Ilixadencel is being developed and tested as a treatment option for patients with renal cell carcinoma and glioblastoma. The medication is currently in clinical development and has already shown promising results in early studies. In addition to ilixadencel, Immunicum is also working on other products developed based on allogeneic cell therapy. This includes therapies for other types of cancer such as liver cancer and pancreatic cancer. The company has also achieved promising results in this area. Overall, Immunicum is an innovative biotech company aiming to develop new and effective cancer therapies. By specifically activating the body's immune system, their goal is to fight cancer cells and improve the quality of life for patients. The company has already made promising developments in this field and continues to work on improving the effectiveness of its therapies. Mendus AB (publ) ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Mendus AB (publ)'s Market Capitalization

Mendus AB (publ)'s market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Mendus AB (publ)'s market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Mendus AB (publ)'s market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Mendus AB (publ)’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Mendus AB (publ) stock

What is the current Mendus AB (publ) market capitalization?

The current market capitalization of Mendus AB (publ) is 189.85 M SEK.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Mendus AB (publ).

How has the market capitalization of Mendus AB (publ) developed in recent years?

The market capitalization of Mendus AB (publ) has increased/decreased by 3.23% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Mendus AB (publ)?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Mendus AB (publ)?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Mendus AB (publ) have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Mendus AB (publ) pay?

Over the past 12 months, Mendus AB (publ) paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mendus AB (publ) is expected to pay a dividend of 0 SEK.

What is the dividend yield of Mendus AB (publ)?

The current dividend yield of Mendus AB (publ) is .

When does Mendus AB (publ) pay dividends?

Mendus AB (publ) pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Mendus AB (publ)?

Mendus AB (publ) paid dividends every year for the past 0 years.

What is the dividend of Mendus AB (publ)?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Mendus AB (publ) located?

Mendus AB (publ) is assigned to the 'Health' sector.

Wann musste ich die Aktien von Mendus AB (publ) kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Mendus AB (publ) from 9/30/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Mendus AB (publ) pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Mendus AB (publ) in the year 2023?

In the year 2023, Mendus AB (publ) distributed 0 SEK as dividends.

In which currency does Mendus AB (publ) pay out the dividend?

The dividends of Mendus AB (publ) are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Mendus AB (publ)

Our stock analysis for Mendus AB (publ) Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mendus AB (publ) Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.